High prevalence of neutralizing activity to Helicobacter pylori cytotoxin in serum of gastric-carcinoma patients.
Helicobacter pylori infection is causally related to chronic type-B gastritis, and may also be associated with an increased risk of gastric carcinoma. Vacuolating cytotoxin, which is an 87-kDa protein secreted by H. pylori, induces eukaryotic cell vacuolation in vitro. To determine whether there is an association between H. pylori vacuolating cytotoxin and gastric carcinoma, we investigated several characteristics of H. pylori infection, i.e., isolation of H. pylori from gastric biopsies, antibodies specific for H. pylori, detection of neutralizing activity to vacuolating cytotoxin in serum and immunological detection of cytotoxin by serum. Out of 6 sera from gastric-carcinoma patients, all showed the neutralizing activity to vacuolating cytotoxin, in contrast to 3 of 5 sera from peptic-ulcer patients. Normal individuals showed no neutralizing activity. All sera possessing the neutralizing activity recognized an 87-kDa protein band by Western blot analysis. Our results confirmed that cytotoxin-neutralizing activity in human sera was associated with immunodetection of an 87-kDa protein. To further evaluate neutralizing activity in serum from gastric-carcinoma patients, we retrospectively analyzed frozen-stocked serum samples from 22 gastric-carcinoma patients. Sera from 21 of these 22 patients exhibited neutralizing activity. These sera were also checked for antibodies to H. pylori, using an ELISA; 16 sera showed positive results. Our results indicate that detection of cytotoxin-neutralizing activity in sera is strongly associated with H. pylori infection, and probably with gastric carcinoma, and is also of interest in the diagnosis of H. pylori infection.
Hirai
M
M
Second Department of Internal Medicine, Fukui Medical School, Japan.
Azuma
T
T
Ito
S
S
Kato
T
T
Kohli
Y
Y
Fujiki
N
N
D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D001426:Bacterial Proteins / Q000276:immunology*; D001427:Bacterial Toxins / Q000276:immunology*; D001706:Biopsy; D015153:Blotting, Western; D002277:Carcinoma / Q000453:epidemiology / Q000209:etiology / Q000276:immunology* / Q000382:microbiology; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology / Q000473:pathology; D006367:HeLa Cells; D016481:Helicobacter Infections / Q000150:complications / Q000453:epidemiology / Q000276:immunology* / Q000382:microbiology; D016480:Helicobacter pylori / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D015995:Prevalence; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000276:immunology* / Q000382:microbiology; D013276:Stomach Ulcer / Q000453:epidemiology / Q000209:etiology / Q000276:immunology / Q000382:microbiology
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001427:Bacterial Toxins; C074689:VacA protein, Helicobacter pylori